Flexion Therapeutics, Inc. (FLXN)
Stock Price:
$12.26 USD
-0.20 (-1.61%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
604.40M |
| Revenue (ttm) |
81.02M |
| Net Income (ttm) |
-141.17M |
| Shares Out |
49.30M |
| EPS (ttm) |
-3.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$12.26 |
| Previous Close |
$12.46 |
| Change ($) |
-0.20 |
| Change (%) |
-1.61% |
| Day's Open |
12.50 |
| Day's Range |
12.22 - 12.61 |
| Day's Volume |
308,120 |
| 52-Week Range |
5.01 - 22.98 |
More Stats
| Market Cap |
604.40M |
| Enterprise Value |
630.46M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.30M |
| Float |
44.10M |
| EPS (basic) |
-3.58 |
| EPS (diluted) |
-3.58 |
| FCF / Share |
-2.98 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.07M |
| Short Ratio |
18.18 |
| Short % of Float |
27.98% |
| Beta |
2.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.46 |
| PB Ratio |
87.97 |
| Revenue |
81.02M |
| Operating Income |
-123.60M |
| Net Income |
-141.17M |
| Free Cash Flow |
-127.37M |
| Net Cash |
-26.06M |
| Net Cash / Share |
-0.53 |
| Gross Margin |
77.76% |
| Operating Margin |
-152.56% |
| Profit Margin |
-174.20% |
| FCF Margin |
-157.21% |
| ROA |
-30.64% |
| ROE |
-486.91% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
11 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.27*
(73.49% upside)
Low
17.0
Current: $12.26
High
35.0
Target: 21.27
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 72.96 | 22.52 | 0.36 | - | - | - | - | - | - |
| Revenue Growth | 223.91% | 6244.79% | - | - | - | - | - | - | - |
| Gross Profit | 63.00 | 15.19 | 0.35 | - | - | - | - | - | - |
| Operating Income | -136 | -159 | -130 | -69.78 | -46.06 | -26.99 | -17.77 | -15.01 | -11.29 |
| Net Income | -150 | -170 | -137 | -71.89 | -46.32 | -27.31 | -18.19 | -14.98 | -11.45 |
| Shares Outstanding | 38.09 | 37.75 | 33.03 | 25.30 | 21.50 | 13.89 | 0.79 | 0.54 | 0.49 |
| Earnings Per Share | -3.93 | -4.49 | -4.16 | -2.84 | -2.15 | -1.97 | -23.02 | -27.58 | -23.26 |
| Operating Cash Flow | -149 | -160 | -108 | -62.47 | -38.95 | -23.14 | -16.19 | -13.98 | -10.35 |
| Capital Expenditures | -3.89 | -0.85 | -2.15 | -8.44 | -5.20 | -0.80 | -0.41 | -0.03 | -0.04 |
| Free Cash Flow | -153 | -161 | -110 | -70.91 | -44.15 | -23.95 | -16.59 | -14.01 | -10.39 |
| Cash & Equivalents | 137 | 259 | 393 | 206 | 111 | 152 | 16.57 | 29.41 | 10.57 |
| Total Debt | 203 | 158 | 160 | 30.53 | 15.00 | 3.56 | 5.05 | - | - |
| Net Cash / Debt | -65.89 | 100 | 233 | 176 | 96.32 | 148 | 11.52 | 29.41 | 10.57 |
| Assets | 218 | 296 | 441 | 226 | 127 | 153 | 18.78 | 30.01 | 10.94 |
| Liabilities | 238 | 186 | 181 | 39.23 | 23.15 | 8.41 | 8.67 | 2.72 | 1.78 |
| Book Value | -20.11 | 110 | 260 | 187 | 104 | 145 | -64.70 | -47.52 | -32.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Flexion Therapeutics, Inc. |
| Country |
United States |
| Employees |
288 |
| CEO |
Michael D. Clayman |
Stock Information
| Ticker Symbol |
FLXN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: FLXN |
| IPO Date |
February 12, 2014 |
Description
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.